menu
    • menu
    [{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Not Applicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"CB5138 Analog peptides","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalyn Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mannkind \/ Not Applicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avalyn Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Nintedanib Esylate

    Menu

    Nintedanib Esylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mannkind

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mannkind

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrosis

                            Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

                            Brand Name : MNKD-201

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 04, 2024

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avalyn Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avalyn Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avalyn Initiates Phase 1b Study for AP02, Novel Inhaled Nintedanib

                            Details : AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

                            Brand Name : AP02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mannkind

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mannkind

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MannKind Proceeds with Phase 1 Nintedanib Dpi Study for Pulmonary Fibrotic Diseases

                            Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

                            Brand Name : MNKD-201

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Accepts Supplemental New Drug Application for OFEV® (nintedanib) for Children and Adolescents Aged 6...

                            Details : OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.

                            Brand Name : Ofev

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 25, 2023

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avalyn Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avalyn Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic ...

                            Details : AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fib...

                            Brand Name : AP02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2023

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data From Boehringer Ingelheim Support the Potential Use of Nintedanib in Children and Adolescents With Fi...

                            Details : The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.

                            Brand Name : Ofev

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 05, 2022

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Blade Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Blade Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cudetaxestat,Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic...

                            Details : No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).

                            Brand Name : BLD-0409

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : Cudetaxestat,Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Study Analysis Available During ATS 2021 Supports Long-Term Treatment with Ofev in Systemic Sclerosis-Associat...

                            Details : In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.

                            Brand Name : Ofev

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2021

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OFEV Receives Positive Recommendation from CADTH and INESSS for the Treatment of Progressive Fibrosing Interst...

                            Details : OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.

                            Brand Name : OFEV

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2021

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Icahn School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Collaborate to Study Nintedanib for Fibrosing...

                            Details : New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient ...

                            Brand Name : Ofev

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : Nintedanib Esylate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Icahn School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth